Boston Trust Walden Corp Grows Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Boston Trust Walden Corp boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 3.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 134,575 shares of the company's stock after buying an additional 4,920 shares during the period. Boston Trust Walden Corp owned 0.43% of Medpace worth $44,710,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. R Squared Ltd purchased a new stake in shares of Medpace during the fourth quarter worth about $30,000. Stone House Investment Management LLC purchased a new stake in Medpace during the 3rd quarter valued at approximately $33,000. Ashton Thomas Securities LLC bought a new stake in shares of Medpace during the third quarter valued at approximately $37,000. Capital Performance Advisors LLP purchased a new position in shares of Medpace in the third quarter worth $46,000. Finally, True Wealth Design LLC boosted its position in shares of Medpace by 16,800.0% during the third quarter. True Wealth Design LLC now owns 169 shares of the company's stock worth $56,000 after acquiring an additional 168 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Performance

NASDAQ MEDP traded down $6.87 on Friday, hitting $354.10. 287,927 shares of the stock were exchanged, compared to its average volume of 220,145. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77. The firm has a market capitalization of $11.01 billion, a P/E ratio of 31.01, a P/E/G ratio of 1.79 and a beta of 1.36. The stock has a fifty day moving average price of $343.61 and a two-hundred day moving average price of $350.38.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Robert W. Baird lifted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Redburn Atlantic initiated coverage on Medpace in a report on Monday, October 14th. They issued a "buy" rating and a $404.00 target price on the stock. TD Cowen dropped their price target on Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a research note on Wednesday, October 23rd. Baird R W downgraded Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. Finally, Truist Financial lowered their target price on Medpace from $415.00 to $397.00 and set a "hold" rating for the company in a research report on Monday, October 14th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.